spacer
home > ict > summer 2018 > regulatory guidance on outsourcing
PUBLICATIONS
International Clinical Trials

Regulatory Guidance on Outsourcing

The landmark guidelines for Good Clinical Practice globally were released by the ICH in 1996 – the now-famous ICH GCP E6. This was the culmination of a number of years’ work by the combined efforts of the regulatory agencies and industry associations of Europe, Japan, and the US, along with consideration of practices in Australia, Canada, the Nordic countries, and the WHO. The aim of the guideline was the harmonisation of regulatory requirements in what was then the regions of the world in which the majority of drug trials were conducted, namely Europe, the US, and Japan.

A review of the guideline reveals that a significant proportion of the document is taken up with describing the roles and responsibilities of various key players in the conduct of a drug trial. Entire sections are given over to the duties of an institutional review board (IRBs)/independent ethics committee (Section 3), an investigator (Section 4), the responsibilities of a sponsor (Section 5), and, within that, the activities associated with monitoring (5.18). The effects of this have been several-fold. The relationship between a sponsor and an investigator has been clearly established and a universal model for how ethics committees/IRBs should be set up and operate has been created. Additionally, the activities associated with monitoring have become the universal blueprint for the job description for a clinical research monitor/associate.

A lot has happened in the clinical research sector since the release of E6. The growth and widespread use of electronic data capture was one of the factors behind the release of EMA’s Reflection Paper on Risk Based Quality Management in Clinical Trials in 2013. Included in the glossary of this document is the definition of central monitoring, a concept that was not readily achievable in 1996 because of the reliance on predominantly paperbased data capture systems at the time. Also, in 2013 and in response to the advances in data capture, the FDA produced its Guidance for Industry, ‘Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring’. As with the EMA document, the subject of centralised monitoring is comprehensively covered, including a list of alternative monitoring techniques.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Martin Robinson is Co-Founder and Executive Vice President at IAOCR. He has worked across the international biopharmaceuticals industry for nearly 30 years, and his extensive experience includes setting up a number of clinical research business ventures. Using his clinical operations and workforce development expertise, Martin is a leading expert in clinical research competence, at an individual and organisational level.
spacer
Martin Robinson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

Clinical Innovation Partnerships

11-12 September 2019, Hotel Palace, Berlin

Clinical Innovation Partnerships is the only event for senior clinical operations and procurement professionals driving innovation in their clinical trials. It is where the pharma, CRO and vendor clinical trials ecosystem meet to drive innovation in digitalisation, tech and partnering to improve patient experience and reduce trial cost and time.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement